Study of Laparoscopic Radical Hysterectomy Based on Space Anatomy in Patients With IB3 and IIA2 Cervical Cancer
Comparison Between Laparoscopic Radical Hysterectomy Based on Space Anatomy and Abdominal Radical Hysterectomy for Stage IB3 and IIA2 Cervical Cancer: a Multicenter Retrospective Cohort Study
1 other identifier
observational
500
0 countries
N/A
Brief Summary
Radical hysterectomy is an effect treatment for FIGO IB3 and IIA2 cervical cancer patients who refuse to receive radical concurrent chemoradiotherapy. However, due to the large tumor size, both patients and surgeons encountered the risk of substantial bleeding, urinary tract damage, and unsatisfactory resection during surgery. Therefore, the exploration of effective and safe surgical treatments is crucial in enhancing the quality of life and prognosis for patients. Laparoscopic radical hysterectomy (LRH) offers the advantages of reduced bleeding and accelerated recovery, thereby minimizing patient discomfort and enhancing their quality of life. However, the prognosis of patients who received LRH or traditional abdominal radical hysterectomy (ARH) remains controversial. We proposed a modified LRH skill based on new space anatomy concept. In our previous single-center study, the result demonstrates that LRH based on space anatomy leads to less intraoperative blood loss and decreased ureteral injury rate compared with traditional skill. The benefits of this new method for patient survival remain uncertain. In this multicenter retrospective study, we aim to assess clinical prognosis and safety of this new LRH compared with traditional abdominal radical hysterectomy (ARH) in FIGO IB3 and IIA2 cervical cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2024
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 27, 2024
CompletedFirst Submitted
Initial submission to the registry
December 28, 2024
CompletedFirst Posted
Study publicly available on registry
January 6, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 15, 2025
CompletedJanuary 6, 2025
December 1, 2024
19 days
December 28, 2024
January 3, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Overall survival
The time from end of surgery to death from any cause.
5 years
Progression-free survival
The time from end of surgery to either the first documented disease progression or death from any cause.
5 years
Secondary Outcomes (2)
Surgery complication rate
Intraoperative or within 2 weeks after surgery
Intraoperative blood loss
Intraoperative blood loss
Study Arms (2)
LRH group
In this group, patients received a modified laparoscopic radical hysterectomy(LRH) based on space antomy.
ARH group
In this group, patients received a traditional abdominal radical hysterectomy(ARH). ARH group is defined as a control group.
Interventions
This is a modified laparoscopic radical hysterectomy based on space anatomy. By identifying the vesicouterine ligament and four associated special spaces, the ureter can be completely liberated from the external aspect of the uterus. This skill not only reduces rate of surgical complications but also facilitates optimal tumor resection.
This producre is a classic and traditional radical hysterectomy.
Eligibility Criteria
Patients who clinically diagnosed with IB3 and IIA2 cervical cancer are retrospectively collected from electronic medical records of four tertiary medical center from January 2012 to January 2022
You may qualify if:
- Aged between 20 to 70 years
- Preoperative clinical diagnosis was FIGO 2018 stage IB3 or IIA2 cervical cancer;
- Patients who received standard Querleu-Morrow type C radical hysterectomy (including ARH or LRH based on space anatomy) and pelvic lymphadenectomy;
- no preoperative suspected lymph nodes metastasis, parametrial involvement or lower 1/3 vagina involvement.
You may not qualify if:
- patients who had active double cancer or uncontrolled serious concurrent disease that might compromise prognosis;
- pregnancy;
- incomplete radical surgery;
- follow-up time less than 6 months or lost to follow-up
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 28, 2024
First Posted
January 6, 2025
Study Start
December 27, 2024
Primary Completion
January 15, 2025
Study Completion
March 15, 2025
Last Updated
January 6, 2025
Record last verified: 2024-12